Goodwin Procter advised STALICLA SA on the deal.STALICLA SA announced its exclusive in-licensing agreement with Novartis to develop mavoglurant as a treatment for substance-use disorder, neurodevelopmental disorders,…
This content is for Standard 1 Year members only. LoginJoin Now
Author: Martina Bellini
…
This content is for Standard 1 Year members only. LoginJoin Now